Table 1 Clinical, laboratory and iron profile characteristics of study cohort, total and stratified by severity of hypoxemia
From: Systemic hypoferremia and severity of hypoxemic respiratory failure in COVID-19
Characteristic | All patients (n = 30) | Severe (n = 10) | Non-severe (n = 20) |  |
|---|---|---|---|---|
Age, median (IQR), years | 57 (52–64) | 57 (53–75) | 57 (52–64) | 0.949 |
Males, n (%) | 17 (57) | 5 (50) | 12 (60) | Â |
Females, n (%) | 13 (33) | 5 (50) | 8 (40) | Â |
APACHE II score, median (IQR) | 13.0 (9.8–15) | 14.5 (12–20) | 13 (12–18) | 0.7512 |
Clinical Frailty Scale, n (%) | ||||
 1 | 23 (77) | 9 (90) | 14 (70) |  |
 2 | 4 (13) | 1 (10) | 3 (15) |  |
 > 3 | 3 (10) | 0 | 3 (15) |  |
Respiratory support, n (%) | ||||
 Non-invasive ventilation | 18 (60) | 7 (701) | 11 (55) | 0.509 |
 Invasive ventilation | 26 (87) | 10 (100) | 16 (80) | 0.378 |
 Prone position | 17 (57) | 10 (100) | 7 (35) | 0.004 |
Advanced cardiovascular support, n (%) | 4 (13) | 0 (0) | 4 (20) | 0.379 |
Advanced renal support, n (%) | 10 (33) | 5 (50) | 5 (25) | 0.271 |
PaO2/FiO2 ratio, median (IQR) | 127.5 (87–200.6) | 82.5 (77–87) | 190.8 (127.5–277.5) | < 0.001 |
Laboratory data (normal range) | ||||
 Haemoglobin (g/L) (120–150), mean (SD) | 130.4 (20.1) | 124.7 (16.7) | 133.2 (21.4) | 0.280 |
 White cell count (× 109/L) (4.0–11.0), mean (SD) | 10.6 (4.8) | 11.0 (5) | 10.4 (4.7) | 0.733 |
 Lymphocyte count (× 109/L) (1.0–4.0), mean (SD) | 0.74 (0.4) | 0.50 (0.2) | 0.87 (0.42) | 0.015 |
 D-dimer (μg/mL) (0–500), median (IQR) | 3286 (1302–14,227) | 9505.5 (845–5023) | 2462 (1453–9850) | 0.462 |
 Fibrinogen (g/L) (1.5–4.0), median (IQR) | 6 (5.5–6.3) | 6 (5.5–6.3) | 6.1 (5.5–6.4) | 0.670 |
 CRP (mg/L) (0–5), mean (SD) | 246.2 (100.1) | 235.8 (101.8) | 251.4 (101.5) | 0.69 |
Iron parameters (normal range) | ||||
 Ferritin (mcg/l) (10–200), median (IQR) | 1476.1 (656.6–2698) | 903.8 (566.9–2789.2) | 1566.1 (729–2511.5) | 0.569 |
 Serum iron (μmol/L) (11–30), median (IQR) | 3.6 (2.5–5) | 2.3 (2.2–2.5) | 4.3 (3.3–5.2) | < 0.001 |
 Transferrin (g/L) (1.8–3.6), median (IQR) | 1.5 (1.1–1.8) | 1.3 (0.8–1.8) | 1.5 (1.1–1.8) | 0.784 |
 Transferrin saturation (%) (16–50), median (IQR) | 9 (7–13) | 7 (6–12) | 12 (8–14) | 0.122 |
Pulmonary embolism, n (%) | 16 (53.5) | 7 (70) | 9 (45) | 0.203 |
Outcome as of 10 May 2020, n (%) | ||||
 Died in ICU | 6 (20) | 5 (50) | 1 (5) |  |
 Still alive in ICU | 16 (53) | 3 (30) | 13 (65) |  |
 Discharged alive from ICU | 8 (27) | 2 (20) | 6 (30) |  |
 ICU length of stay, median (IQR), days | 8 (4–11) | 7 (4–9) | 9 (4–12) |  |